fbpx Roadmap for research and care | Progress In Mind

Roadmap for research and care

Precision medicine is essential to the optimization of care for individual patients, but also in the efficient use of trials to develop new treatments much needed in psychiatry, Professor Arango (University Hospital Gregorio Marañón, Madrid, Spain) said during a State of the Art Lecture at EPA 2020.

For many diseases, most notably cancer, drug development has been led by understanding of gene mutations and pathophysiology, but in psychiatry it has tended to be achieved through clinical observation.

That said, the value of clinical observation should not be underestimated as a starting point. After all, the Research Domain Criteria (RDoC) project arises from the idea that symptoms crossing diagnostic boundaries – such as the cognitive dysfunction common to major depression and schizophrenia –  share disorders of neural circuitry which reflect common cellular, molecular and ultimately genetic abnormalities.1

Enriching populations

Low glutathione levels predict cortical loss

And there are areas of psychiatry where understanding of etiological mechanisms is being used to enrich populations for clinical trials. One example – related to the possible role of oxidative stress in the development of schizophrenia -- is that of glutathione, where low levels seem to predict loss of cortical volume in people vulnerable to early onset psychosis.2

Target enrichment in a trial population is well and good but -- since individual response to treatment is dynamic -- we need to measure factors relevant to response not only at baseline but also during the course of treatment.3

Secondly, we need trials that allow adaptive treatment, so that patients not responding can be re-randomized to an add-on or alternative therapy.

Real-time data not subject to biased recall

Acquisition of real time data by passive monitoring poses problems of integration

And, thirdly, in predicting and measuring outcomes we need more precise measurement -- such as can now be achieved by the high-intensity, real-time monitoring of behavior through wearable devices – rather than episodic recall measures such as PANSS that are so subject to bias and unintended inaccuracy. This poses problems of integrating large amounts of data from multiple sources, but in this task machine learning is coming to our aid.

Those pursuing precision medicine have placed much faith in genetics. But we must not oversell its potential, Professor Arango cautioned.

If the lifetime risk of schizophrenia is around 1%,4 a genetic risk score that confers a twenty-fold increase means that an individual still has an 80% chance of not developing the disorder.

Pragmatic advances precede full understanding

In another example drawn from schizophrenia, there has been interest in the presence of the genetic deletion syndrome 22q11, which identifies a relatively homogeneous group of patients with shared etiology. But only 0.3% of people with schizophrenia have this deletion.5

On the other hand, there is no reason to be too pessimistic. It took twenty years to fully realize the benefits of targeted HER2 therapy in women whose breast tumours over-express the growth factor. It is often the case that advances can be achieved pragmatically, before underlying mechanisms are fully understood.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

  1. Insel T, et al. American J Psychiatry 2010;167:748–751
  2. Fraguas D, et al. Schizophr Res 2012;137:58-65
  3. Lenze EJ, et al. JAMA Psychiatry 2020; March 25
  4. McGrath J, et al. Epidemiol Rev 2008;30:67-76  
  5. Fraguas D, et al. Psychol Med 2017; 47: 193–197
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country